ACAD * Stock Overview
A biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$509.00 |
| 52 Week High | US$509.00 |
| 52 Week Low | US$509.00 |
| Beta | 0.64 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 60.54% |
| 33 Year Change | -43.29% |
| 5 Year Change | n/a |
| Change since IPO | -39.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACAD * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 60.5% | 0% | 0% |
Return vs Industry: ACAD * exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: ACAD * exceeded the MX Market which returned 3.7% over the past year.
Price Volatility
| ACAD * volatility | |
|---|---|
| ACAD * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ACAD * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ACAD *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 540 | Steve Davis | www.acadia.com |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
| ACAD * fundamental statistics | |
|---|---|
| Market cap | Mex$68.75b |
| Earnings (TTM) | -Mex$1.99b |
| Revenue (TTM) | Mex$9.88b |
7.0x
P/S Ratio-34.6x
P/E RatioIs ACAD * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACAD * income statement (TTM) | |
|---|---|
| Revenue | US$550.90m |
| Cost of Revenue | US$298.66m |
| Gross Profit | US$252.24m |
| Other Expenses | US$363.05m |
| Earnings | -US$110.81m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.68 |
| Gross Margin | 45.79% |
| Net Profit Margin | -20.12% |
| Debt/Equity Ratio | 0% |
How did ACAD * perform over the long term?
See historical performance and comparison